Skip to main content
    N

    Nektar Therapeutics (NKTR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $35.91
    -0.53 (-1.45%)

    Market Cap: $1.25B

    Last updated: Nov 17, 2026 at 4:33 PM ET

    Nektar Therapeutics (NKTR) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Nektar Therapeutics (NKTR) has a market cap of $1.25B and an enterprise value of $1.21B. Its share count is up 80.39% from a year earlier. It kept -339.67% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 2.78% below the market cap, as cash exceeds debt.

    Market Cap$1.25B
    Enterprise Value$1.21B
    Latest price (Nov 17, 2026)$35.91

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 12, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 3.40% in the quarter ended Sep 30, 2026 and grew 56.53% a year over 2 years.

    Shares Outstanding34.18M
    Shares Change (YoY)+80.39%
    Shares Change (QoQ)+3.40%
    Share Count Growth (2Y CAGR)+56.53%

    Valuation Ratios

    Sales and book value multiples are 23.5x and 1.4x. Its year-end P/S ranged from 1.2x to 40.8x from 2016 to 2025.

    P/S Ratio23.5x
    Forward P/S30.4x
    P/B Ratio1.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 36.64% over 52 weeks and trades 23.48% below its 50-day average.

    Beta (1Y)1.06
    52-Week Change-36.64%
    1-Month Change-1.99%
    3-Month Change-52.80%
    6-Month Change-46.86%
    5-Year Change-82.90%
    10-Year Change-79.09%
    Total Return (1Y)-36.64%
    Total Return (3Y CAGR)+70.66%
    Total Return (5Y CAGR)-27.28%
    Return vs SPY (1Y)-50.87%
    Max Drawdown (1Y)-64.34%
    Max Drawdown (3Y)-73.20%
    Sharpe Ratio (1Y)-0.64
    Correlation with SPY (1Y)0.19
    50-Day Average$46.93
    200-Day Average$65.04
    52-Week Range$33.40 to $109.00
    RSI (14 Days)34.4
    Average Volume (20 Days)625.94K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 9.00x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio9.00x
    Quick Ratio9.00x
    Debt / Equity0.00x
    Interest Coverage-5.28x

    Returns and Efficiency

    Return on equity is -20.86% and return on assets is -17.09% over the last 12 months.

    Return on Equity (ROE)-20.86%
    Return on Assets (ROA)-17.09%
    Return on Capital Employed (ROCE)-17.41%
    ROA (5Y Average)-53.14%
    Asset Turnover0.08x

    Scores

    NKTR has an Altman Z-Score of -1.12, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-1.12
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $52.19M over the last 12 months is down 16.64% from the 12 months before.

    Revenue$52.19M
    Revenue Growth (YoY)-16.64%
    Gross Profit$52.19M
    Operating Income-$166.86M
    Pretax Income-$173.14M
    Net Income-$177.26M
    EBIT-$167.40M
    Reported EPS (TTM)-$6.42

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 81.70% of the $1.04B in total assets.

    Cash and Equivalents$34.69M
    Total Debt$0
    Net Cash$34.69M
    Net Cash Per Share$1.01
    Working Capital$603.86M
    Shareholder Equity$849.72M
    Book Value Per Share$24.86
    Total Assets$1.04B
    Total Liabilities$187.53M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $528.00K of capital spending, operating cash flow left -$257.49M of free cash flow.

    Operating Cash Flow-$256.96M
    Capital Expenditures$528.00K
    Free Cash Flow-$257.49M
    FCF Per Share-$7.54
    Depreciation and Amortization$11.31M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -319.75%.

    Gross Margin100.00%
    Operating Margin-319.75%
    Pretax Margin-331.78%
    Net Margin-339.67%
    EBIT Margin-320.78%
    FCF Margin-493.41%
    Gross Margin (5Y Average)76.68%

    Growth

    Revenue fell 15.66% a year over 3 years.

    Revenue Growth (3Y CAGR)-15.66%
    Revenue Growth (5Y CAGR)-18.43%
    Book Value Per Share Growth (2Y CAGR)-34.40%
    Tangible Book Per Share Growth (2Y CAGR)-34.40%

    Revenue and profit by year

    Dividends and Yields

    NKTR does not pay a dividend. Its free cash flow yield is -20.98%.

    FCF Yield-20.98%
    Buyback Yield-76.04%
    Shareholder Yield-76.04%

    Stock Splits

    The last split was a 1-for-15 reverse split on Jun 9, 2025.

    Last Split DateJun 9, 2025
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 10 similar companies, NKTR has the 4th highest P/S.

    P/S Ratio23.5x vs 13.2x median
    Revenue Growth (Trailing 4 Quarters, YoY)-16.64% vs +15.80% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 0.01% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+0.01%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About NKTR

    What is NKTR's market cap?

    Nektar Therapeutics has a market cap of $1.25B. Its enterprise value, which adds debt and subtracts cash, is $1.21B.

    How many shares of NKTR are outstanding?

    Nektar Therapeutics has 34.18M shares outstanding. The count is up 80.39% from a year earlier.

    Does NKTR pay a dividend?

    No. Nektar Therapeutics does not pay a dividend.

    How much debt does NKTR have?

    Nektar Therapeutics has $0 of total debt and $34.69M of cash and equivalents, a net cash position of $34.69M.